Rationale: Two categories of cardiac stem cells (CSCs) with predominantly myogenic (mCSC) and vasculogenic (vCSC) properties have been characterized in the human heart. However, it is unknown whether functionally competent CSCs of both classes are present in the myocardium of patients affected by end-stage cardiac failure, and whether these cells can be harvested from relatively small myocardial samples. 
T he human heart possesses 2 classes of cardiac stem cells (CSCs), which have powerful but distinct vasculogenic and myogenic properties. 1, 2 One category of CSCs is nested in vascular niches distributed throughout the coronary circulation and is primarily responsible for the turnover of endothelial cells (ECs) and smooth muscle cells (SMCs), and vasculogenesis, 2 ie, vasculogenic (v)CSCs. The other CSC pool is clustered in niches located in the myocardial interstitium and regulates myocyte renewal and cardiomyogenesis, 1 ie, myogenic (m)CSCs. These CSCs can be isolated from samples, Ϸ75 to 130 mg, of atrial and ventricular myocardium of patients undergoing elective cardiac surgery. 1, 2 This method of CSC harvesting is currently used in a phase I clinical trial, which includes patients with ischemic cardiomyopathy undergoing coronary bypass surgery. 3 Here, we sought to determine whether functionally competent CSCs can be obtained from patients with advanced heart failure and whether sufficient quantities can be collected from endomyocardial biopsies. Affirmative answers to these questions would support the possibility that nonthoracotomy biopsies could serve as a source of autologous CSCs for the potential treatment of patients with advanced cardiomyopathies.
senescence, and apoptosis were determined to define the growth properties of these cells.
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Results

Human Samples
Biopsies of the right portion of the septum or apex of the left ventricle (LV) were harvested ex vivo from explanted hearts (nϭ13) or following removal of the LV apical region at the time of left ventricular assist device implantation (nϭ7). The characteristics of the patients are listed in Online Table I . Two-five biopsies were collected, yielding a total sample weight of 4.8Ϯ1.0 mg (Online Figure I) . Based on previous results, Ͻ100 CSCs were present in each sample. 4 Specimens were dissociated and the unfractionated cell population was expanded for 17Ϯ2 days (Online Figure I ). Cells were sorted for c-kit and characterized by FACS 11Ϯ2 days later (Online Figure I ), when 5ϫ10 6 cells were obtained ( Figure 1A ). c-kit-positive cells were negative for markers of hematopoietic and mesenchymal lineages; Ϸ3% expressed KDR ( Figure 1B ). c-kit-positive cells and cells positive for c-kit and KDR corresponded to mCSCs and vCSCs, respectively. 2 vCSCs were amplified for an additional 13Ϯ3 days (Online Figure I ) to obtain 5ϫ10 6 cells ( Figure  1C ). Both classes of CSCs were obtained in all 20 cases studied.
Growth Properties of mCSCs and vCSCs
The growth of stem cells is regulated by the length of their telomeres and the level of telomerase activity. 5 Thus, these variables were measured in CSCs together with population doubling time (PDT) and the fraction of cycling cells. PDT was comparable in mCSCs and vCSCs, averaging 27 and 28 hours, respectively ( Figure 1D ). Additionally, Ϸ7% to 8% mCSCs and vCSCs were positive for 5-bromodeoxyuridine (BrdUrd) ( Figure  1E and 1F). Telomere length, measured by flow-FISH, 6 showed that mCSCs and vCSCs had telomeres varying from 5.3 to 7.7 kbp (Figure 2A through 2D), far from telomere lengths of 1.5 to 2 kbp, which are associated with replicative senescence of human cells. 5 The slightly shorter average telomere length in vCSCs was consistent with the higher number of divisions required for the expansion of this stem cell pool.
Telomerase activity was evaluated by quantitative PCR and was expressed as number of template copies normalized for the TSR8 oligonucleotide. The catalytic activity of the ribonucleoprotein was high in both mCSCs and vCSCs ( Figure 2E ). Importantly, enzyme activity was similar to that measured in mCSCs isolated from large surgical specimens of patients with modest alterations in ventricular function. 1 These human mCSCs have been shown to regenerate extensive areas of infarcted myocardium, differentiating into functionally competent cardiomyocytes and coronary vessels. 1, 2, 7 The well-preserved telomere-telomerase axis in mCSCs and vCSCs was consistent with the relatively low levels of cells positive for the senescence-associated protein p16
INK4a
, which prevents permanently reentry of stem cells into the cell cycle. 1 Similarly, apoptosis was low ( Figure 3A through 3D) . Thus, mCSCs and vCSCs expanded in culture to a clinically relevant number possess a significant capacity for further growth.
Differentiation of mCSCs and vCSCs
The commitment of mCSCs and vCSCs was assessed by FACS analysis. Before differentiation, mCSCs and vCSCs were negative for cardiac lineages ( Figure 4A and 4B) . However, mCSCs exposed to dexamethasone became predominantly c-kit-negative and expressed myocyte-specific transcription factors and contractile proteins. Small fractions of cells were positive for transcription factors, and membrane and cytoplasmic proteins specific of SMCs and ECs. Similarly, in the presence of dexamethasone, vCSCs lost largely c-kit and KDR and expressed transcription factors, and membrane and cytoplasmic proteins specific of SMCs and ECs. Additionally, some cells were positive for transcription factors and contractile proteins typical of cardiomyocytes ( Figure 4C and 4D) . Collectively, mCSCs formed 5-fold more myocytes than vCSCs, and vCSCs formed 4-fold more SMCs and 3.2-fold more ECs than mCSCs ( Figure 4E ). Comparable differences in lineage specification of mCSCs and vCSCs were found when these stem cell classes were obtained from large surgical specimens. 1,2
Discussion
The present study had 2 objectives: (1) to determine whether patients with severe heart failure retain a pool of functionally competent mCSCs and vCSCs in the diseased myocardium; and (2) to establish whether in these patients with advanced heart failure, undergoing either cardiac transplantation or left ventricular assist device implantation, mCSCs and vCSCs can be isolated from small myocardial biopsies and expanded in vitro to a clinically relevant number for subsequent autologous delivery. Our results provide a positive answer to both questions, raising the possibility that autologous mCSC and vCSC therapy is feasible and can be considered for research evaluation in patients with advanced heart failure.
We have emphasized repeatedly that the telomere-telomerase axis is a major determinant of the growth behavior of mCSCs and vCSCs. Based on extensive characterization of mCSCs, we have shown that these cells undergo an average telomeric shortening of 130 bp per population doubling. 1 Critical telomere length associated with growth arrest and cellular senescence of mCSCs and human hematopoietic stem cells varies from 2.0 to 1.5 kbp. 1, 5 In this study, mCSCs and vCSCs at the end of expansion had telomere length of Ϸ6 kbp. It can be predicted that mCSCs and vCSCs can undergo 31 additional population doublings (6Ϫ2ϭ4 kbp /0.13 kbpϭ31 population doublings) before irreversible growth arrest is reached. Therefore, human CSCs can be extensively grown in vitro and implanted in vivo before a major loss in their proliferation potential.
Importantly, both classes of human CSCs, mCSCs and vCSCs, have been obtained from specimens of tissue weighing Ϸ5 mg and, following amplification, rapidly reached a value of 5ϫ10 6 cells in Ϸ40 days. The time factor involved in the acquisition of a therapeutically applicable number of mCSCs and vCSCs constitutes a limitation for the management of acute events but does not preclude the treatment of chronic heart failure. Currently, one million mCSCs are delivered by intracoronary infusion to patients with postinfarction ischemic cardiomyopathy and impaired ventricular function. 3 The number of mCSCs being used is significantly smaller than that of mononuclear bone marrow cells, 240ϫ10 6 , injected in an identical manner in subjects with acute myocardial infarction or chronic heart failure. 8 Pools of 12.5 and 25ϫ10 6 autologous cardiac cells, derived from the in vitro expansion of cardiospheres, 9 are administrated to patients with recent myocardial infarction and depressed cardiac function (ClinicalTrials.gov Identifier: NCT00893360). The unproven hypothesis views cardiac progenitors as potentially more specific and effective in the direct restoration of damaged myocardium, or in the indirect activation of endogenous mCSCs, resulting in an identical tissue regenerative response. 10 Both mechanisms may also be operative although, independently from the clinical outcome, it will be essentially impossible to define the actual role of mCSCs or cardiospheres in myocardial repair.
The recognition that human CSCs are active and widely distributed throughout the myocardium is at variance with their inefficient regenerative capacity following ischemic and nonischemic myocardial injury. Although a direct explanation for this growth defect cannot be provided, human CSCs are properly equipped to regulate tissue homeostasis, 11 but are largely inadequate to promote cardiac repair. By delivering 5ϫ10 6 human CSCs, we may increase their frequency in the myocardium by several-fold.
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